Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib and Romidepsin in Relapsed/Refractory T-cell Lymphoma
NCT03770000Phase 2Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Mar 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenalisib in T-cell lymphoma, sponsored by Rhizen Pharmaceuticals AG. Started Mar 2019; status: completed.
02
Drugs
tenalisib
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT03770000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770000.